Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review

The advent of immune-checkpoint inhibitors (ICIs) targeting the programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) axis, produced a paradigm change of the treatment algorithm for metastatic, non-oncogene addicted, non-small cell lung cancer (NSCLC). However, the majority of patients with on...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Transl Lung Cancer Res
Huvudupphovsmän: Leone, Gianmarco, Passiglia, Francesco, Bironzo, Paolo, Bertaglia, Valentina, Novello, Silvia
Materialtyp: Artigo
Språk:Inglês
Publicerad: AME Publishing Company 2020
Ämnen:
Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7815346/
https://ncbi.nlm.nih.gov/pubmed/33489826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr-20-710
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk